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The sites of degradation of human low density lipoprotein (LDL), are analyzed using the novel abelling 
compound 0-(4-diazo-3-[L2SI]iodobenzoyl)sucrose (D1251BS). The decay from rat serum of D1Z9BS-labelled 
LDL is identical to the serum decay of conventionally iodinated (ICl method) LDL. The radioactivity de- 
rived from Diz51BS-labelled LDL accumulates predominantly in the liver after intravenous injection and 
the hepatic radioactivity remains associated with the lysosomal compartment for an extended period of time, 
when compared to the radioactivity derived from conventionally iodinated LDL. It is concluded that the 
D9BS labelling procedure is an interesting new tool to study the sites of catabolism of serum lipoproteins. 
Low density lipoprotein Catabolic site Methodology Liver Iodination 
0-(4-Diazo-3-[‘2’I]iodobenzoyl)sucrose 
1. INTRODUCTION 
Recently a number of labelling compounds were 
developed specifically designed to study the 
catabolic sites of serum proteins [l-4]. These com- 
pounds contain either a sucrose [ 1,2], a raffinose 
[3] or a cellobiose [4] moiety, are not or only slow- 
ly degraded by lysosomal enzymes and do not 
readily pass through lysosomal and cellular mem- 
branes [S]. Thus, when such a radioactive molecule 
is attached to a serum protein, and the labelled 
protein is subsequently injected intravenously, 
radioactivity will accumulate within the cells 
catabolizing this protein. Here, the application of 
the Dlz51BS label for the study of the sites of 
catabolism of LDL in the rat is evaluated. 
2. MATERIALS AND METHODS 
LDL was isolated from human plasma by se- 
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Abbreviations: LDL, low density lipoprotein; DIBS, O- 
(4-diazo-3-iodobenzoyl)sucrose 
quential ultracentrifugation in a Beckman 50.2 Ti 
rotor in the non-protein solvent density interval of 
1.019-1.063 g/ml, washed once and dialyzed ex- 
tensively against saline, containing 1 mM EDTA 
(pH 7.4), prior to radioiodination with 1311 using 
the ICI method as in [7]. O-(CAminobenzoyl)- 
sucrose was radioiodinated as in [2]. 500 ~1 of a 
solution of 0-(4-amino-3-[1251]iodobenzoyl)suc- 
rose (containing 6.5 nmol) was converted to 
D1251BS by mixing with 20~1 of 1 M NaN02 and 
20~1 of 1 N HCl for 1 min at 0°C. The reaction 
was stopped by the addition of 50,ul of 1 M 
NaHCOs. 500~1 of this mixture was added to 
300 ~1 LDL containing 0.15 mg protein in 0.5 M 
Na-borate buffer (pH 10.0) and kept at 0°C for 
1 h. The coupling reaction was stopped by addi- 
tion of 5 ~1 of 2% NaN3 solution. After 1 h at 
37’C, the LDL-bound D12’IBS was separated 
from the mixture by chromatography on a Se- 
phadex G-50 column equilibrated with 0.15 M 
NaCl containing 8 mM phosphate, pH 7.4. 
In all metabolic studies both D’251BS-labelled 
LDL and conventionally iodinated LDL (not the 
same molecule), labelled with 13rI using the ICI 
method, were investigated simultaneously. The 
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rats (male, Wistar), weighing 250-300 g, main- 
tained on standard rat chow, were fasted for 
18-24 h prior to each experiment. All radioactive 
LDL preparations were ‘screened’ in vivo before 
use in metabolic studies. For this purpose 18-24 h 
fasted rats were injected intravenously with l-2 ml 
radioiodinated LDL (0.15-0.30 mg protein). The 
blood was collected 1 h after injection, serum was 
isolated and used immediately for the actual ex- 
periment. At different time intervals after injection 
of the labelled proteins the blood was collected and 
a number of tissues (heart, lungs, liver, spleen, 
kidneys, jejunum, fat pad, muscle, hide, adrenals 
and testes) were excised, weighed and counted foi, 
radioactivity. 
After bleeding of the rats a 20% (w/v) liver 
homogenate was made in 0.25 M sucrose using a 
Potter-Elvehjem homogenizer with a Teflon pestle 
and the homogenate was fractionated by differen- 
tial centrifugation according to [8]. Average 
recovery of cathepsin activity, protein and radioac- 
tivity in the subcellular fractions from the 
homogenate were 109, 93 and 98070, respectively. 
Cathepsin activity was measured from the rate of 
production of radioactive amino groups from 
HDL-apoprotein at pH 3.8 [9]. The lipid- 
associated radioactivity of iodinated LDL was 5.8 
f 2.9% or 4.7 f 1.4% (means f SD for 3 separate 
preparations) for conventionally iodinated or 
D’251BS-labelled LDL, respectively. Screening 
decreased these values by about 50%. The remain- 
ing LDL radioactivity was quantitatively 
precipitated using tetramethylurea. Na12’I 
(350-600 mCi/ml) and Na1311 (40 mCi/ml), both 
carrier free, were obtained from Amersham Inter- 
national, Amersham, England. 
3. RESULTS 
Monoexponential serum decays were observed 
after intravenous injection of both D’251BS- and 
1311-labelled human LDL (not shown). The serum 
half-lives of both radiolabelled LDL preparations 
were identical (9.5 h; average value for two ex- 
periments for each label). 
In fig. 1 the tissue accumulation of radioactivity 
derived from the DIBS-labelled and the conven- 
tionally iodinated LDL are shown for the liver and 
the kidneys. The kidneys are an example of a tissue 
in which the percentage of the injected dose of 
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Fig. 1. Accumulation of intravenously injected D”‘IBS- 
labelled LDL (0) and “‘I-iodinated LDL (0) in the 
liver and the kidneys. At different ime intervals after 
injection, blood was collected and a number of tissues, 
among others the kidneys and the liver, were excised, 
weighed and counted for radioiodine. The DIBS- 
dependent accumulation of radioactivity (0) in each 
tissue at each individual time-point was calculated as 
described in section 3. Mean values + SD for 3 
experiments are presented. 
D1251BS- and 1311-labelled LDL is not statistically 
different at any time point. However, in the liver 
we see, after an initial sharp rise for both labels, a 
decrease of the radioiodine derived from the con- 
ventionally labelled LDL, while the radioactivity 
derived from the DIBS-labelled LDL continues to 
increase. Subtraction of the hepatic radioactivity 
derived from the conventionally iodinated LDL 
((r/o of injected dose) from the 070 of the injected 
dose coming from DIBS-labelled LDL results in a 
calculated value which we have called the DIBS- 
dependent accumulation of radioactivity. The only 
tissue besides the liver that showed any DIBS- 
dependent accumulation of LDL radioactivity was 
the spleen. 6 h after injection this tissue ‘ac- 
cumulated’ only 0.6 +_ 0.1% of the injected dose, 
while 4.6 + 0.2% accumulated in the liver. 
To test if the DIBS-dependent accumulation is a 
measure of radioiodine present within the 
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lysosomal compartment, the liver was analyzed by 
subcellular fractionation 30 min and 4 h after in- 
jection of labelled LDL. As is evident from fig.2, 
most of the radioactivity (derived from both 
D”‘IBS and 1311) was recovered in the soluble frac- 
tion of the liver shortly (30 min) after injection. In 
contrast, 4 h after injection of labelled LDL a con- 
siderable part of the radioactivity derived from 
D’251BS-labelled LDL was recovered in the 
lysosomal fraction, while little radioiodine derived 
from the conventionally iodinated LDL was found 
in this fraction. The .DIBS-dependent accumula- 
tion 4 h after injection of the labelled LDL (fig.2, 
bottom) therefore occurred intracellularly in 
association with the lysosomal compartment. Fig.2 
also shows the distribution of a lysosomal marker 
enzyme (cathepsin) for comparison. Other 
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Fig.2. Subcellular fractionation of the liver 30 min (left 
panel) and 4 h (right panel) after intravenous injection 
of D”‘IBS-LDL and I31 I-LDL. Blocks from left to right 
represent subcellular fractions in the order in which they 
were isolated: nuclear, mitochondrial, light mitochon- 
drial or lysosomal, microsomal and final supernatant 
fractions. The relative protein content is given on the 
abscissa. The ordinate gives the relative specific activity 
(vo of total recovered activity divided by % of total 
recovered protein). 
lysosomal marker enzymes, e.g., acid phosphatase 
and deoxyribonuclease, showed a similar distribu- 
tion as cathepsin, while the distribution of the 
microsomal (glucose-6-phosphatase), mitochon- 
drial (glutamate dehydrogenase) and plasma mem- 
brane (5 ’ -nucleotidase) marker enzymes were iden- 
tical to those described in [8] (not shown). 
4. DISCUSSION 
Here the DIBS-labelling technique was 
evaluated for the study of the tissue sites of 
catabolism of LDL in the rat. In our hands the 
DIBS labelling was a simple and reliable procedure 
with an efficiency of labelling of all preparations 
of approx. 10%. The serum decay of DIBS- 
labelled LDL in the rat was identical to the serum 
decay of LDL labelled with the ICI method, in- 
dicating that the DIBS label does not influence the 
in vivo turnover of LDL. The serum decay of 
human LDL in the rat has a half-life of approx. 
9.5 h. As a consequence a large fraction of LDL is 
still present in the circulation 4-6 h after injection. 
Moreover, the intravenously injected LDL will 
equilibrate with the extravascular space. To study 
the intracellular accumulation of radioiodine in 
tissues it is essential to correct for all extracellular 
label, including that present in interstitial fluid and 
bound to the outside of the plasma membrane. It 
is however extremely difficult to remove all serum 
proteins from, e.g., the liver, even by extensive 
perfusion of this organ [lO,l 11. It was therefore 
decided to apply a mathematical correction for the 
radioiodine present extracellularly. The D12’IBS- 
derived tissue radioactivity represents the sum of 
extracellular radioactivity and intracellularly ac- 
cumulated radioactivity. The 1311C1-derived label 
represents predominantly extracellular adioactivi- 
ty. By subtracting the i3iI value from the 1251 value 
(both as Vo of the injected dose) one obtains a 
value for the intracellular accumulation of 
degradation products of the labelled serum pro- 
tein. This was named the DIBS-dependent ac- 
cumulation. This value may underestimate the in- 
tracellular accumulation to some extent since a 
small amount of 13i I is present inside the cells and 
since a small amount of 1251 leaks out of the cells 
during a 4-6 h experiment. Because serum LDL is 
bound in a reversible way to plasma membrane 
receptors, it can be expected that LDL present in 
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contaminating blood, as well as LDL bound ex- 
tracellularly, will be recovered in the soluble frac- 
tion after subcellular fractionation. The hepatic 
radioactivity derived from labelled serum LDL was 
indeed almost quantitatively recovered in the solu- 
ble fraction if measured 30 min after injection (see 
fig.f), indicating that the radioactivity was not 
associated with any intracellular organelle. 4 h 
after injection the fraction of the radioactivity 
derived from the D’251BS-labelled LDL equivalent 
with the DIBS-dependent accumulation was 
associated with the lysosomal compartment (fig.2). 
This indicates that the calculated value called the 
DIBS-dependent accumulation of radioactivity 
represents the lysosomal accumulation of the 
catabolic products of injected DIBS-labelled LDL. 
Previously LDL catabolism has been studied us- 
ing [14C]sucrose label [1,12]. It was found that the 
liver was the most active organ for LDL degrada- 
tion. This study provides further evidence for the 
important role of the liver in LDL catabolism. A 
major advantage of the DIBS-labelling procedure 
for the study of catabolic sites is the radioisotope 
used. Radioiodine is generally used for the la- 
belling of serum lipoproteins and the metabolism 
of conventionally 13’1-iodinated and D”‘IBS-la- 
belled proteins can be compared directly in a 
double label experiment. 
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